RKDA Arcadia Biosciences, Inc.
Beverages · Nasdaq · SEC CIK 1469443 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.1%
TTM net income YoY-101.9%
TTM EPS YoY9.4%
Revenue 3-yr CAGR3.5%
Net income 3-yr CAGR—
Margins
Gross margin41.1%
Operating margin-68.9%
Net margin-202.1%
FCF margin—
EBITDA margin-68.7%
Returns
ROE-260.8%
ROA-153.9%
ROIC (approx.)-142.0%
Asset turnover0.76x
Leverage & solvency
Liabilities / assets49.0%
Debt / equity0.00x
Current ratio3.58x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.35x
Accruals ratio-100.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $4.86M | $5.04M |
| Cost of revenue | $3.10M | $2.96M |
| Gross profit | $1.76M | $2.08M |
| R&D expense | $9,000 | $53,000 |
| SG&A expense | $7.00M | $9.64M |
| Operating income | -$2.50M | -$3.65M |
| Pretax income | -$2.33M | -$4.31M |
| Income tax | $8,000 | $8,000 |
| Net income | -$2.34M | -$7.04M |
| EBITDA | -$2.47M | -$3.59M |
| EPS (basic) | -1.71 | -5.17 |
| EPS (diluted) | -1.71 | -5.17 |
| Weighted avg. shares (diluted) | 1.37M | 1.36M |
| Banking | ||
| Net interest income | $221,000 | $782,000 |
| Balance sheet | ||
| Cash & equivalents | $259,000 | $4.24M |
| Short-term investments | $4.30M | $0 |
| Inventory | $1.21M | $904,000 |
| Current assets | $6.36M | $9.24M |
| PP&E, net | $8,000 | $41,000 |
| Intangibles | $39,000 | $39,000 |
| Total assets | $6.55M | $13.52M |
| Current liabilities | $2.06M | $2.56M |
| Total liabilities | $2.41M | $7.29M |
| Shareholders' equity | $4.14M | $6.22M |
| Shares outstanding | 1.37M | 1.36M |
| Cash flow statement | ||
| Operating cash flow | -$4.74M | -$9.63M |
| Capital expenditure | $0 | $16,000 |
| Free cash flow | -$4.74M | -$9.64M |
| Investing cash flow | $750,000 | $7.34M |
| Financing cash flow | $6,000 | $9,000 |
| Depreciation & amortization | $32,000 | $58,000 |
| Stock-based compensation | $234,000 | $512,000 |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.